GREAT MINDS
THINK DIFFERENTLY

With a collective wealth of industry success, knowledge, and drive, our leaders share a passion for reinvigorating healthcare.

SCOTT TARRIFF

Founder, Chief Executive Officer and Director

  • Scott Tarriff Founder, Chief Executive Officer and Director

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

    Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

    In 2016, Scott was awarded the prestigious Ernst and Young Entrepreneur Of The Year® Award in the Specialty Pharmaceutical category, New Jersey. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance, and personal commitment to their businesses and communities.

    Scott holds a BS in marketing from Pennsylvania State University and an MBA from Rider College.

DAVID PERNOCK

President, Chief Operating Officer

  • David Pernock President, Chief Operating Officer

    David has been our President and Chief Operating Officer since January 2017. David brings a wealth of pharmaceutical and biotechnology experience to the Eagle leadership team, having previously served as a member of the board from April 2015 through December 2016. David’s strategic focus and entrepreneurial spirit has contributed to the commercial success of many products throughout his distinguished career.

    Before joining Eagle, David served as Chairman of the board of directors and CEO (2010-2017) of Fibrocell Science, Inc., a publicly traded autologous cell and gene therapy company.

    David previously held various positions at GlaxoSmithKline, most notably serving as Senior Vice President of the Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions. He also served as President of Reliant Pharmaceuticals and as a director of Martek Biosciences Corporation.

    David holds a BS in business administration from Arizona State University.

PETE A. MEYERS

Chief Financial Officer

  • Pete A. Meyers Chief Financial Officer

    Pete joined Eagle in May 2017 with more than 2 decades of experience in the healthcare industry. From 2016 to 2017, he served as Chief Financial Officer of Motif BioSciences, Inc. Prior to joining Motif, Pete spent 3 years as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation.

    Pete has 18 years of experience as a healthcare investment banker, including Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Pete currently serves on the board of directors and chairs the Audit Committee of Immutep Ltd.

    Pete holds a BS in finance from Boston College and an MBA in finance from Columbia Business School.

MICHAEL W. CORDERA

Executive Vice President
General Counsel
Chief Compliance Officer

  • Michael W. Cordera Executive Vice President
    General Counsel
    Chief Compliance Officer

    Mike joined Eagle in April 2016 as Deputy General Counsel and was promoted to General Counsel and Chief Compliance Officer in March 2018. Prior to joining Eagle, he held various legal positions with increasing responsibility at Warner Chilcott plc (2010–2014) and inVentiv Health (2014–2016).

    From 2001 until 2009, Mike was an associate at Shearman & Sterling LLP, where he focused on litigation and finance.

    Mike earned a BA in international affairs from The American University of Paris and his JD from Rutgers School of Law—Newark.

ADRIAN HEPNER, MD, PhD

Executive Vice President
Chief Medical Officer

  • Adrian Hepner, MD, PhD Executive Vice President
    Chief Medical Officer

    Adrian has over 25 years of experience in US and international clinical research and drug development. He has been our Chief Medical Officer since January 2015. His experience includes the development and implementation of the clinical and regulatory strategies for a multiple number of products from early-stage development through successful New Drug Application (NDA) and EU regulatory filings.

    Prior to Eagle, Adrian’s roles included Vice President of Clinical Research at Avanir Pharmaceuticals, Vice President of Clinical Research and Medical Affairs at BioDelivery Sciences International (BDSI), and Senior Medical Director at UCB BioSciences, Inc. Additionally, he spent 17 years in neuropsychiatry, private practice.

    Adrian has published more than 20 papers and has been issued several patents for his work.

    Adrian received his MD and PhD from the University of Buenos Aires. He spent a number of years as a post-doctoral fellow in Neuro-Psychopharmacology at the University of Ottawa. Additionally, Adrian completed visiting research physician experiences in the Department of Psychiatry at Harvard Medical School and the Department of Neurology at the National Institute of Mental Health.

DANIEL O’CONNOR

Chief Strategy Officer
Head of Corporate Development

  • Daniel O’Connor Chief Strategy Officer
    Head of Corporate Development

    Dan is our Chief Strategy Officer and Head of Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.

    Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.

    Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.

MICHAEL MORAN

Executive Vice President
Sales, Business Development
and Government Affairs

  • Michael Moran Executive Vice President
    Sales, Business Development
    and Government Affairs

    Mike joined Eagle in January 2016 as Vice President, Sales and was promoted to Executive Vice President, Sales, Business Development and Government Affairs in August 2019.  Mike has a lengthy record of success in the pharmaceutical industry.  Prior to joining Eagle, Mike held various positions with increasing responsibility at GlaxoSmithKline, Reliant Pharmaceuticals, Muro and Astra Zeneca.

    Mike earned his B.S. in Business Management from the State University of New York at Empire and completed the Transformational Leadership for Executives program at the University of Pennsylvania Wharton School of Business.

BOARD OF
DIRECTORS

MICHAEL GRAVES

Chairman of the Board
Executive Committee Chair
Nominating and Corporate Governance Committee Chair
Compensation Committee Chair

  • Michael Graves Chairman of the Board
    Executive Committee Chair
    Nominating and Corporate Governance Committee Chair
    Compensation Committee Chair

    Mike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of Paddock Laboratories, Inc., and multiple leadership positions leading to President of the Generic Products Division at Par Pharmaceutical from 1998 to 2006.

SCOTT TARRIFF

Chief Executive Officer
Board Member
Executive Committee

  • Scott Tarriff BOD Chief Executive Officer, Board Member, Executive Committee

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

    Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

RICHARD A. EDLIN, J.D.

Board Member, Compensation Committee,
Nominating and Corporate Governance Committee

  • Richard A. Edlin, J.D. Board Member
    Compensation Committee
    Nominating and Corporate Governance Committee

    Rich is currently the Vice Chair, Chair of Litigation Practice in New York and the Business & Regulatory Financial Services Litigation Group, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP.

    Rich is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center; a trustee of The Carnegie Council for Ethics in International Affairs; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of New Jersey SEEDS, among other professional and community activities.

ROBERT L. GLENNING

Board Member, Audit Committee, Nominating
and Corporate Governance Committee

  • Robert L. Glenning Board Member
    Audit Committee
    Nominating and Corporate Governance Committee

    Bob has over 30 years of experience in the healthcare industry and currently serves as President of the Financial Services and Information Technology Divisions and CFO at Hackensack Meridian Health, the most comprehensive healthcare delivery network in the state of New Jersey. He previously served as Executive Vice President and CFO of Hackensack University Health Network. From 2002 to 2007, Bob served as EVP and CFO of Kaleida Health, Inc. Prior to Kaleida Health, he served as VP and CEO of Acute Care at Northeast Health and Albany Memorial Hospital. Robert began his career at PricewaterhouseCoopers.

     

STEVEN RATOFF

Board Member, Audit Committee Chair, Compensation Committee

  • Steven Ratoff Board Member
    Audit Committee Chair
    Compensation Committee

    Steve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its Chairman. Prior to NovaDel, Steve held various executive positions with Cima Labs, Inc., MacroMed, Inc., and Brown-Forman Corporation. In 2004, Steve began his ongoing tenure as a venture partner of ProQuest Investments.

JENNIFER SIMPSON, PhD

Board Member, Nominating and
Corporate Governance Committee

  • JENNIFER SIMPSON, PhD Board Member
    Nominating and Corporate Governance Committee

    Dr. Simpson has been President and CEO of Delcath and a member of the board since May 2015.  She previously served as interim President and Chief Executive Officer, joining Delcath in 2012 as Executive Vice President, Global Marketing.

    Prior to Delcath, Dr. Simpson served in positions of increasing responsibility at ImClone Systems (a subsidiary of Eli Lilly and Company), most recently as Vice President, Global Marketing, Oncology Brand Lead, where she was responsible for product commercialization activities and launch preparation for one of their late stage assets. Prior to ImClone, Dr. Simpson was Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech focused on innovative solutions in immunology, oncology and nephrology.

    Early in her career, she spent over a decade as a hematology/oncology nurse practitioner and educator. Dr. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.